Open access · CC-BY
via OpenAlex
Mitochondrial dysfunction in the striatum of aged chronic mouse model of Parkinson’s disease
Frontiers in Aging Neuroscience · 2009 · ▲ 21 citations
Abstract
Mitochondrial oxidative stress and dysfunction has been implicated as a possible mechanism for the onset and progression of Parkinson-like neurodegeneration. However, long-term mitochondrial defects in chronic animal neurodegenerative models have not been demonstrated. In this study, we investigated the function of striatal mitochondria 6 weeks after the induction of a chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease (MPD). Although severe depression of mitochondrial respiration was observed immediately after acute administrations of MPTP, we failed to detect a significant mitochondrial inhibition in presence of striatal dopamine (DA) deficit 6 weeks after the chronic MPD induction in young adult mice. In contrast, when aged mice were chronically treated with MPTP and at 6 weeks post-treatment, these animals suffered an inhibition of the basal (state 4) and adenosine 5'-diphosphate-stimulated (state 3) respiration and a fall in adenosine triphosphate level in the striatal mitochondria. The aged chronic MPD also brought about a sustained diminution of striatal anti-oxidant enzyme levels including that of superoxide dismutases and cytochrome c. The mitochondrial deficits in the striatum of aged chronic MPD 6 weeks after treatment were further correlated with significant losses of striatal DA, tyrosine hydroxylase, DA uptake transporter, and with impaired movement when tested on a challenging beam. Our findings suggest that MPTP may trigger the neurodegenerative process by obstructing the mitochondrial function; however, striatal mitochondria in young animals may potentially rejuvenate, whereas mitochondrial dysfunction(definition) is sustained in the aged chronic MPD. Therefore, the aged chronic MPD may serve as a suitable investigative model for further elucidating the integral relationship between mitochondrial dysfunction and neurodegenerative disorder, and for assessing the therapeutic efficacy of mitochondrial protective agents as potential neuroprotective drugs.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.3389/neuro.24.003.2009
- Canonical
- link ↗
- Fetched
- 2026-10-05 MST
Cite this
APA
Patki, G. (2009). Mitochondrial dysfunction in the striatum of aged chronic mouse model of Parkinson’s disease. <em>Frontiers in Aging Neuroscience</em>. https://doi.org/10.3389/neuro.24.003.2009
Vancouver
Patki G. Mitochondrial dysfunction in the striatum of aged chronic mouse model of Parkinson’s disease. Frontiers in Aging Neuroscience. 2009. doi:10.3389/neuro.24.003.2009.
BibTeX
@article{gaurav2009Mitoch,
title = {Mitochondrial dysfunction in the striatum of aged chronic mouse model of Parkinson’s disease},
author = {Gaurav Patki},
journal = {Frontiers in Aging Neuroscience},
year = {2009},
doi = {10.3389/neuro.24.003.2009},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
bioRxiv (Cold Spring Harbor Laboratory) 2021
Preprint · OA
DROSOPHILA MTOR COMPLEX 2 PRESERVES MITOCHONDRIAL AND CARDIAC FUNCTION UNDER HIGH FAT DIET TREATMENT
Equine Veterinary Journal 2026
Citation only
Mitochondrial dysfunction in equine ageing: Current evidence and clinical implications for geroscience
Equine veterinary journal 2026
Citation only
Mitochondrial dysfunction in equine ageing: Current evidence and clinical implications for geroscience.
Free radical biology & medicine 2026
Citation only
Cyclophilin D (CypD) promotes mitochondrial impairment, synaptic defects, cognitive loss, and tau pathology during aging.
International Journal of Molecular Sciences 2024
Open access · CC-BY
Mitochondrial Dysfunction as a Potential Mechanism Mediating Cardiac Comorbidities in Parkinson’s Disease
Frontiers in Pharmacology 2019
Open access · CC-BY